[Adverse effects of drug interactions of cyclosporin A and tacrolimus therapy]
- PMID: 11126995
[Adverse effects of drug interactions of cyclosporin A and tacrolimus therapy]
Abstract
In recent years cyclosporin A and tacrolimus therapy have been more and more popular in immunosuppressive treatment and in management of various diseases. Most often both drugs are administered to patients on polytherapy. Despite the very strong activity of these medications and common adverse effects, the literature on the subject infrequently associates these phenomena with the possibility of interaction with other drugs or factors causing changes in cyclosporin A, tacrolimus or their metabolites levels in the blood, or else with changes in other pharmacokinetic parameters. It seems that drug monitored therapy will significantly decrease the occurrence of adverse effects, and in the future it may possibly explain whether such effects are the consequence of drug interaction. The paper presents the interactions between cyclosporin A and tacrolimus on the one hand, and other medications or factors which change the blood concentration values or other pharmacokinetic parameters of both drugs.
Similar articles
-
The side-effects of ciclosporine-A and tacrolimus.Clin Nephrol. 1998 Jun;49(6):356-63. Clin Nephrol. 1998. PMID: 9696431 Review.
-
Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant recipients.Biol Blood Marrow Transplant. 2006 Mar;12(3):325-34. doi: 10.1016/j.bbmt.2005.10.022. Biol Blood Marrow Transplant. 2006. PMID: 16503502 Clinical Trial.
-
Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.J Heart Lung Transplant. 2009 Jun;28(6):598-604. doi: 10.1016/j.healun.2009.03.014. J Heart Lung Transplant. 2009. PMID: 19481021
-
Effects of immunosuppressive drugs on platelet aggregation and soluble P-selectin levels in renal transplant patients.Ren Fail. 2009;31(2):111-7. doi: 10.1080/08860220802599163. Ren Fail. 2009. PMID: 19212907
-
Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference.Ther Drug Monit. 2009 Apr;31(2):139-52. doi: 10.1097/FTD.0b013e318198d092. Ther Drug Monit. 2009. PMID: 19177031